Non Hodgkin’s Lymphoma Market

 Market Overview:

The 7 major Non Hodgkin’s lymphoma markets reached a value of US$ 4.0 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 7.4 Billion by 2034, exhibiting a growth rate (CAGR) of 5.71% during 2024-2034.

The Non Hodgkin’s lymphoma market has been comprehensively analyzed in IMARC’s new report titled “Non Hodgkin’s Lymphoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034”. Non Hodgkin’s lymphoma (NHL) is a type of cancer that affects the lymphatic system, which is part of the body's immune system. It is characterized by the uncontrolled growth of lymphocytes that may lead to the formation of tumors in the lymph nodes, bone marrow, spleen, and liver. There are several subtypes of NHL, which can be broadly categorized into two main groups: B-cell NHLs and T-cell NHLs. The symptoms of the disease can vary depending on the type and stage of cancer, as well as the location and size of the tumors. Some of the common symptoms that are indicative of NHL are swollen lymph nodes, fever, night sweats, fatigue, weight loss, persistent itching, abdominal pain or swelling, etc. The diagnosis typically involves several tests and procedures, including blood tests, biopsy, imaging tests, flow cytometry, etc. Additionally, numerous imaging tests, such as X-rays, CT scans, MRI scans, PET scans, etc., can assist in identifying the location, size, and extent of the tumors as well as the health of surrounding tissues and organs. In some cases, a bone marrow biopsy may be required to determine the spread of cancer in the bone marrow.

The rising incidences of several types of blood cancer and the inflating unmet need for novel therapies with improved safety profiles are primarily driving the global Non Hodgkin’s lymphoma market. In addition to this, the escalating utilization of molecular diagnostics for diagnosing NHL since it provides detailed information about the specific subtype of NHL, which is important for determining the best course of treatment, is further propelling the market growth. Moreover, the widespread adoption of targeted therapy, that uses drugs to target specific genetic mutations in cancer cells to treat certain subtypes of NHL, such as mantle cell lymphoma, is creating a positive outlook for the market. Apart from this, the emerging popularity of stem cell transplantation for treating NHL patients who have a relapsed or refractory form of the disease is also acting as a significant growth-inducing factor. Additionally, the ongoing advancements in biopsy techniques, including the introduction of fine-needle aspiration and core needle biopsy, which make it easier for healthcare providers to obtain tissue samples for diagnosis, are further bolstering the market growth. Besides this, the increasing adoption of innovative immune checkpoint inhibitors since they significantly improve progression-free survival in patients with NHL as compared to other treatments is expected to drive the global Non Hodgkin’s lymphoma market in the coming years.

IMARC Group’s new report provides an exhaustive analysis of the Non Hodgkin’s lymphoma market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for Non Hodgkin’s lymphoma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Non Hodgkin’s lymphoma market in any manner.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the Non Hodgkin’s lymphoma market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the Non Hodgkin’s lymphoma market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current Non Hodgkin’s lymphoma marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the Non Hodgkin’s lymphoma market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the Non Hodgkin’s lymphoma market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the Non Hodgkin’s lymphoma market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of Non Hodgkin’s lymphoma across the seven major markets?
• What is the number of prevalent cases (2018-2034) of Non Hodgkin’s lymphoma by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of Non Hodgkin’s lymphoma by gender across the seven major markets?
• What is the number of prevalent cases (2018-2034) of Non Hodgkin’s lymphoma by type across the seven major markets?
• How many patients are diagnosed (2018-2034) with Non Hodgkin’s lymphoma across the seven major markets?
• What is the size of the Non Hodgkin’s lymphoma patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of Non Hodgkin’s lymphoma?
• What will be the growth rate of patients across the seven major markets?
   

Non Hodgkin’s Lymphoma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for Non Hodgkin’s lymphoma drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Non Hodgkin’s lymphoma market?
• What are the key regulatory events related to the Non Hodgkin’s lymphoma market?
• What is the structure of clinical trial landscape by status related to the Non Hodgkin’s lymphoma market?
• What is the structure of clinical trial landscape by phase related to the Non Hodgkin’s lymphoma market?
• What is the structure of clinical trial landscape by route of administration related to the Non Hodgkin’s lymphoma market?